User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

All Publications

Displaying 12 results.
    • Speech
    A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks is effective: A Belgian prospective study
    Westhovens, Rene[UCL] Durez, Patrick[UCL] Devogelaer, Jean-Pierre[UCL] Van den Bosch, F. Corluy, L Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Vastesaeger, N. (2004) Annual European Congress of Rheumatology (EULAR 2004) — Berlin (Germany)
    • Journal article
    DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
    Cruyssen, BV Van Looy, S. Wyns, B Westhovens, Rene[UCL] Durez, Patrick[UCL] Van den Bosch, F. Veys, Éric M. Mielants, H. DE Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaeger, N. Geldhof, A. Boullart, L. De Keyser, F. (2005) Arthritis Research & Therapy — Vol. 7, no. 5, p. R1063-R1071 (2005)
    • Speech
    Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect
    Cruyssen, B. Vander Durez, Patrick[UCL] Westhovens, Rene[UCL] Van den Bosch, F. Mielants, H. De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaegere, N. Geldhof, A. De Keyser, F. (2006) Annual European Congress of Rheumatology (EULAR 2006) — Amsterdam (Netherlands)
    • Journal article
    Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    Martino, Silvana Cauley, Jane A. Barrett-Connor, Elizabeth Powles, Trevor J. Mershon, John Disch, Damon Secrest, Roberta J. Cummings, Steven R. Mautalen, Carlos A. Zanchetta, J.R. Hooper, Michael J. Ng, Kong Wa Prince, Richard L. Nicholson, Geoffrey Roberts, Anthony P. Seeman, Ego Williamson, Margaret Boschitsch, E. Leb, Georg Body, J.J. Devogelaer, Jean-Pierre[UCL] Geusens, P. Kaufman, Jean-Marc Peretz, A. Adachi, Jonathan Bensen, William Brown, Jacques P. Cheung, Angela Chik, Constance Gee, Shirl Hanley, David Hawker, Gillian A. Hodsman, Anthony B. Joyce, Carol Monchesky, Theodore C. Olszynski, Wojciech P. Roe, Bruce Senikas, Vyte Seminoski, Kerry Wall, Jack Stepan, Jan Hyldstrup, L. Langdahl, Bente Sorensen, Tine Hog Alhava, Esko Kormano, Martti Salmela, Pasi Salmi, Jorma Valimaki, Matti Audran, M. Briancon, D. Delmas, P. Fardellone, Patrice Ribot, C. De Vernejoul, M.C. Balogh, Adam Julesz, J. Szuecs, J. Karsik, Avraham Fiore, Carmelo Genazzani, Andrea Riccardo Gennari, C. Isaia, Giovanni Carlo Melis, Gian Benedetto Nuti, Ranuccio Oriente, Pasquale Passeri, Mario Sartori, Leonardo Corea-Rotter, R. Gonzalez, Santos Murillo, Alfonso Jonker, J.J. Lips, P. Mulder, H. Pols, H.A. Halse, Johan Inge Hoiseth, Arne Jorde, Rolf Olford, Erik Snorre Skag, Arne Stakkestad, Jacob Andreas Wist, Erik Badurski, Janusz Edward Hoszowski, Krzysztof Ogonowski, Jaroslaw Bose, Kamal Lee, Kok Onn Dzurik, Rastislav Kocijancic, Andreja Cannata Andia, Jorge B. Collado, Ramon Carreras Carranza, Frederico Hawkins Diez-Perez, Adolfo Escobar-Jimenez, Fernando Minguella, Jordi Farrerons Solan, Xavier Nogues Torres, Manuel Munoz Larsson, Karin Malströem, Dan (2004) National Cancer Institute. Journal (Print) — Vol. 96, no. 23, p. 1751-1761 (2004)
    • Journal article
    Timing of DAS28 in infliximab therapy: reply
    Durez, Patrick[UCL] Van den Bosch, F. Corluy, L Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Devogelaer, Jean-Pierre[UCL] Vastesaeger, N. Geldhof, A. Westhovens, Rene[UCL] (2005) Rheumatology — Vol. 44, no. 9, p. 1204-1204 (2005)
    • Speech
    Long-term safety of infliximab (INX) with methotrexate (MTX) in a large belgian observational patient cohort with severe, refractory rheumatoid arthritis (RA)
    Durez, Patrick[UCL] Devogelaer, Jean-Pierre[UCL] Vander Cruyssen, B. Vandenbosch, F. Vastesaeger, N. Geldhof, A. De Keyser, F. Verbruggen, L. De Clerck, L. Peretz, A. Malaise, Michel Van Heuverbeke, F. Westhovens, Rene[UCL] (2006) Annual European Congress of Rheumatology (EULAR 2006) — Amsterdam (Netherlands)
    • Speech
    Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients
    Cruyssen, B. Vander Durez, Patrick[UCL] Van Looy, S. Wijns, B. Westhovens, Rene[UCL] Van den Bosch, F. Mielants, H. De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaeger, N. Geldhof, A. Boullart, L. De Keyser, F. (2006) Annual European Congress of Rheumatology (EULAR 2006) — Amsterdam (Netherlands)
    • Speech
    Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population
    Vander Cruyssen, B. Durez, Patrick[UCL] Westhovens, Rene[UCL] Van den Bosch, F. Mielants, H. De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Dewulf, L. Vastesaeger, N. Geldhof, A. Noel, W. Boullart, L.[UCL] De Keyser, F. (2008) —
    • Speech
    Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients
    Vander Cruyssen, B. Durez, Patrick[UCL] Devogelaer, Jean-Pierre[UCL] Van Looy, S. Westhovens, Rene[UCL] Van den Bosch, F. Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaeger, N. Geldhof, A. Boulart, L De Keyser, F. (2005) Annual European Congress of Rheumatology — Vienna (Austria)
    • Journal article
    A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study
    Durez, Patrick[UCL] Van den Bosch, F. Corluy, L Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Devogelaer, Jean-Pierre[UCL] Vastesaeger, N. Geldhof, A. Westhovens, Rene[UCL] (2005) Rheumatology — Vol. 44, no. 4, p. 465-468 (2005)
    • Journal article
    Définition, critères de qualité, évaluation d'un programme de type école du dos. Recommandations de la Société belge des Ecoles du Dos
    Henrotin, Marc[FUNDP] Vanderthommen, Marc Fauconnier, C. Grisart, Jacques[UCL] Masquelier, Etienne[UCL] Peretz, A. Tousaint, F. Lemaître, D. Angenot, P. Mahieu, G. Rossion, P. Bailly, D. Mahy, J.L. Chif, D. Dechef, P. Crielaard, J.M. (2001) Revue du rhumatisme — no.68, p. 168-191 (2001)
    • Speech
    Safety of combination of methotrexate (MTX) and infliximab (IFX) in a large Belgian observational patient cohort with refractory rheumatoid arthritis.
    Durez, Patrick[UCL] Vandenbosch, F. Corluy, L Van den Bossche, N Schuerwegh, A De Clerck, L. Peretz, A. Malaise, Michel Devogelaer, Jean-Pierre[UCL] Westhovens, Rene[UCL] (2002) 66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals — NEW ORLEANS (Louisiana)